ForPatients
by Roche

Solid Tumors Tumor

A study to look at how safe different doses of the study medicine (MOXR0916) were for patients with solid tumor cancer that had spread and did not respond to previous treatment(s), and how this medicine was processed by the body

A Study to Assess Safety and Pharmacokinetics of MOXR0916 in Participants With Locally Advanced or Metastatic Solid Tumors

Trial Status	Trial Runs In	Trial Identifier
Completed	6 Countries	NCT02219724 2014-001474-34 GO29313

The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.

Trial Summary:

This is a first-in-human, Phase 1, open-label, multicenter, dose-escalation study designed to evaluate the safety, tolerability, and pharmacokinetics of MOXR0916 administered intravenously in participants with locally advanced or metastatic solid tumors that have progressed after all available standard therapy or for which standard therapy has proven to be ineffective or intolerable, or is considered inappropriate. This study will consist of a screening period, an initial treatment period, a re-treatment period (for participants who discontinue MOXR0916 after demonstration of prolonged clinical benefit), and a post-treatment follow-up period. Participants will be enrolled in two stages: a dose-escalation stage and an expansion stage. The planned duration of the study is approximately 3 years.

Genentech, Inc.	Phase 1
Sponsor	Phase

NCT02219724 2014-001474-34 GO29313
Trial Identifiers

Eligibility Criteria:

Gender	Age	Healthy Volunteers
All	>=18 Years	No

MOXR0916 is a new medicine (immunotherapy) designed to work on the immune system. Researchers wanted to find out what dose of MOXR0916 was safe to give to cancer

© 2022 F. Hoffmann-La Roche Ltd

patients and what effects, good and/or bad, it had on patients and on their cancers. This was the first time MOXR0916 was given to humans.

© 2022 F. Hoffmann-La Roche Ltd